Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion

Cover Page

Cite item


Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a  progressive course and commonly result in disability. Therefore, their early diagnosis with the assessment of a  clinical phenotype and unfavorable prognostic factors and the timely initiation of therapy are important. The paper provides the expert consensus on the definition of the early stage of Ps, PsA, and IBDs, their treatment goals and main unfavorable prognostic factors. It also gives the rationale for the early use of biological agents in patients with immune-mediated inflammatory diseases.

About the authors

D. I. Abdulganieva

Kazan Medical University

Author for correspondence.
Email: diana_s@mail.ru
ORCID iD: 0000-0001-7069-2725

Diana I. Abdulganieva – MD, PhD, Professor, Head of Chair of Hospital Therapy 

49 Butlerova ul., Kazan, Republic of Tatarstan, 420012

Russian Federation

A. L. Bakulev

V.I. Razumovsky Saratov State Medical University

Email: fake@neicon.ru
ORCID iD: 0000-0002-1450-4942

Andrey L. Bakulev – MD, PhD, Professor, Chair of Dermatovenereology and Cosmetology 

112 Bol'shaya Kazach'ya ul., Saratov, Saratovskaya oblast', Privolzhskiy federal'nyy okrug, 410012

Russian Federation

E. A. Belousova

Moscow Regional Research and Clinical Institute (MONIKI)

Email: eabelous@yandex.ru
ORCID iD: 0000-0003-4523-3337

Elena A. Belousova – MD, PhD, Professor, Head of Department of Gastroenterology; Head of Chair of Gastroenterology, Postgraduate Training Faculty 

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

A. V. Veselov

National Medical Research Centre for Coloproctology named after A.N. Ryzhikh

Email: fake@neicon.ru
ORCID iD: 0000-0003-3115-1787

Alexey V. Veselov – Head of Department of Organization, Education and Development of Coloproctological Service 

2 Salyama Adilya ul., Moscow, 123423

Russian Federation

T. V. Korotaeva

Research Institute of Rheumatology named after V.A. Nasonova

Email: tatianakorotaeva@gmail.com
ORCID iD: 0000-0003-0579-1131

Tatiana V. Korotaeva – MD, PhD, Leading Research Fellow, Laboratory of Innovative Methods for Diagnosis and Treatment of Psoriatic Arthritis 

34A Kashirskoe shosse, Moscow, 115522

Russian Federation

A. M. Lila

Research Institute of Rheumatology named after V.A. Nasonova;
Russian Medical Academy of Continuous Professional Education

Email: fake@neicon.ru
ORCID iD: 0000-0002-6068-3080

Aleksander M. Lila – MD, PhD, Professor, Director Research Institute of Rheumatology named after V.A. Nasonova; Head of Chair of Rheumatology Russian Medical Academy of Continuous Professional Education

34A Kashirskoe shosse, Moscow, 115522; 
2/1–1 Barrikadnaya ul., Moscow, 125993

Russian Federation

E. Yu. Loginova

Research Institute of Rheumatology named after V.A. Nasonova

Email: fake@neicon.ru
ORCID iD: 0000-0001-6875-4552

Elena Yu. Loginova – MD, PhD, Senior Research Fellow, Laboratory of Spondylarthritis and Psoriatic Arthritis 

34A Kashirskoe shosse, Moscow, 115522

Russian Federation

E. V. Sokolovskiy

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: fake@neicon.ru
ORCID iD: 0000-0001-7610-6061

Evgeny V. Sokolovskiy – MD, PhD, Professor, Head of Chair and Clinic of Dermatovenereology 

6–8 L'va Tolstogo ul., Saint Petersburg, 197022

Russian Federation

M. M. Khobeysh

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: mkhobeysh@yandex.ru
ORCID iD: 0000-0001-8670-7223

Marianna M. Khobeysh – MD, PhD, Associate Professor, Chair and Clinic of Dermatovenereology 

6–8 L'va Tolstogo ul., Saint Petersburg, 197022

Russian Federation

M. V. Shapina

National Medical Research Centre for Coloproctology named after A.N. Ryzhikh

Email: fake@neicon.ru
ORCID iD: 0000-0003-1172-6221

Marina V. Shapina – MD, PhD, Head of Department of Research in Inflammatory and Functional Bowel Disorders 

2 Salyama Adilya ul., Moscow, 123423

Russian Federation

O. B. Shchukina

City Clinical Hospital No. 31 (Saint Petersburg)

Email: fake@neicon.ru

Oksana B. Shchukina – MD, PhD, Head of Center of Inflammatory Bowel Disease 

3 Dinamo prospekt, Saint Petersburg, 197110

Russian Federation


  1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590.
  2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583): 263–71. doi: 10.1016/S0140-6736(07)61128-3.
  3. Olivieri I, D'Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9):531–42. doi: 10.1038/nrrheum.2014.106.
  4. van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020;22(1):18. doi: 10.1186/s13075-020-2103-8.
  5. Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14(2):254–66. doi: 10.1093/ecco-jcc/jjz131.
  6. Kemp K, Dibley L, Chauhan U, Greveson K, Jäghult S, Ashton K, Buckton S, Duncan J, Hartmann P, Ipenburg N, Moortgat L, Theeuwen R, Verwey M, Younge L, Sturm A, Bager P. Second N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis. J Crohns Colitis. 2018;12(7):760–76. doi: 10.1093/ecco-jcc/jjy020.
  7. Drescher H, Lissoos T, Hajisafari E, Evans ER. Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers. J Nurse Pract. 2019;15(9):676–81. doi: 10.1016/j.nurpra.2019.07.015.
  8. Theede K, Burisch J. Defining success in treating patients with inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13(7):645–7. doi: 10.1080/1744666X.2017.1317594.
  9. Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):351–61.e5. doi: 10.1053/j.gastro.2016.09.046.
  10. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–9. doi: 10.1046/j.1087-0024.2003.09102.x.
  11. Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176(3):650–8. doi: 10.1111/bjd.15021.
  12. Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, Martínez-Alonso M, Garí E, Portero-Otín M, Santamaria-Babi L, Casanova-Seuma JM. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019;33(1):128–35. doi: 10.1111/jdv.15159.
  13. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–32. doi: 10.1136/annrheumdis-2014-205675.
  14. Dubreuil M, Rho YH, Man A, Zhu Y, Zhang Y, Love TJ, Ogdie A, Gelfand JM, Choi HK. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford). 2014;53(2):346–52. doi: 10.1093/rheumatology/ket343.
  15. Xue Y, Jiang L, Cheng Q, Chen H, Yu Y, Lin Y, Yang X, Kong N, Zhu X, Xu X, Wan W, Zou H. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One. 2012;7(10):e46740. doi: 10.1371/journal.pone.0046740.
  16. Peluso R, Iervolino S, Vitiello M, Bruner V, Lupoli G, Di Minno MN. Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol. 2015;34(4):745–53. doi: 10.1007/s10067-014-2652-9.
  17. Bernstein CN, Benchimol EI, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Kaplan GG. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. J Can Assoc Gastroenterol. 2019;2(Suppl 1):S73–80. doi: 10.1093/jcag/gwy053.
  18. Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017;23(33):6137–46. doi: 10.3748/wjg.v23.i33.6137.
  19. Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C, Nielsen OH, Gislason GH, Hansen PR. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS One. 2013;8(2):e56944. doi: 10.1371/journal.pone.0056944.
  20. Olivieri I, Padula A, D'Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009;83:28–9. doi: 10.3899/jrheum.090218.
  21. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1(1):10–20. doi: 10.1016/j.crohns.2007.06.005.
  22. Белоусова ЕА, Абдулганиева ДИ, Алексеева ОП, Алексеенко СА, Барановский АЮ, Валуйских ЕЮ, Головенко АО, Головенко ОВ, Жигалова ТН, Князев ОВ, Куляпин АВ, Лахин АВ, Ливзан МА, Лубянская ТГ, Николаева НН, Никитина НВ, Никулина ИВ, Осипенко МФ, Павленко ВВ, Парфенов АИ, Рогачиков ЮЕ, Светлова ИО, Ткачев АВ, Ткаченко ЕИ, Халиф ИЛ, Чашкова ЕЮ, Щукина ОБ, Язенок НС, Яковлев АА. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5): 445–63. doi: 10.18786/2072-0505-2018-46-5-445-463.
  23. Щукина ОБ. Дифференциально-диагностические и прогностические критерии клинических форм болезни Крона [диссертация]. Санкт-Петербург; 2017. 399 с.
  24. Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, Laurent V, Zallot C, Peyrin-Biroulet L, Danese S. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. J Crohns Colitis. 2017;11(3): 274–80. doi: 10.1093/ecco-jcc/jjw185.
  25. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–50. doi: 10.1136/annrheumdis-2013-204858.
  26. Tillett W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, McHugh N. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis. 2013;72(8):1358–61. doi: 10.1136/annrheumdis-2012-202608.
  27. Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417–23. doi: 10.1001/jamadermatol.2018.3631.
  28. Ko JS, Uberti G, Napekoski K, Patil DT, Billings SD. Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 years. J Cutan Pathol. 2016;43(11):946–55. doi: 10.1111/cup.12777.
  29. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20 Suppl 4:36–42. doi: 10.1111/j.1365-2036.2004.02044.x.
  30. Burisch J, Ungaro R, Vind I, Prosberg MV, Bendtsen F, Colombel JF, Vester-Andersen MK. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. J Crohns Colitis. 2017;11(10):1200–4. doi: 10.1093/ecco-jcc/jjx066.
  31. Российское общество дерматовенерологов и косметологов. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд. М.: Деловой экспресс; 2016. 768 с.
  32. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii14–7. doi: 10.1136/ard.2004.032482.
  33. Zhu TY, Li EK, Tam LS. Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol. 2012;2012:714321. doi: 10.1155/2012/714321.
  34. Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153–66. doi: 10.1038/s41584-019-0175-0.
  35. Насонов ЕЛ, Коротаева ТВ, Лила АМ, Кубанов АА. Можно ли предотвратить развитие псориатического артрита у пациентов с псориазом? Научно-практическая ревматология. 2019;57(3):250–4. doi: 10.14412/1995-4484-2019-250-254.
  36. Абдулганиева ДИ, Бакулев АЛ, Белоусова ЕА, Знаменская ЛФ, Коротаева ТВ, Круглова ЛС, Кохан ММ, Лила АМ, Хайрутдинов ВР, Халиф ИЛ, Хобейш ММ. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;12(3):4–18. doi: 10.14412/1996-7012-2018-3-4-18.
  37. Чамурлиева МН, Коротаева ТВ, Логинова ЕЮ, Баткаев ЭА. Алгоритм диагностики псориатического артрита в клинической практике дерматолога. Российский журнал кожных и венерических болезней. 2016;19(1):36–40. doi: 10.18821/1560-9588-2016-19-1-36-40.
  38. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460–8. doi: 10.1093/rheumatology/keg384.
  39. Lubrano E, Mesina F, Caporali R. Clinical remission in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2018;36(5):900–10.
  40. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113(4):481– 517. doi: 10.1038/ajg.2018.27.
  41. Peyrin-Biroulet L. Why should we define and target early Crohn's disease? Gastroenterol Hepatol (N Y). 2011;7(5):324–6.
  42. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–40. doi: 10.1080/00365520802600961.
  43. Andrews JM. Le plus ca change: why we need better biomarkers to predict outcomes in ulcerative colitis. J Gastroenterol Hepatol. 2011;26(7):1085–6. doi: 10.1111/j.1440-1746.2011.06754.x.
  44. Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012;38(2):373–86. doi: 10.1016/j.rdc.2012.05.005.
  45. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis. 2002;61(7):630–4. doi: 10.1136/ard.61.7.630.
  46. Логинова ЕЮ, Коротаева ТВ. Ранний псориатический артрит. Научно-практическая ревматология. 2008;46(6):47–55. doi: 10.14412/1995-4484-2008-490.
  47. Jadon DR, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, Jobling A, Shaddick G, Bi J, Winchester R, Giles JT, McHugh NJ. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017;76(4):701–7. doi: 10.1136/annrheumdis-2016-209853.
  48. Elnady B, El Shaarawy NK, Dawoud NM, Elkhouly T, Desouky DE, ElShafey EN, El Husseiny MS, Rasker JJ. Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years. Clin Rheumatol. 2019;38(6):1627–35. doi: 10.1007/s10067-019-04445-0.
  49. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107(12):1770–6. doi: 10.1038/ajg.2012.117.
  50. Бакулев АЛ. Псориаз: клинические особенности, факторы риска и ассоциированные коморбидные состояния. Клиническая фармакология и терапия. 2019;(1):35–9. doi: 10.32756/0869-5490-2019-1-35-39.
  51. Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandía JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46(6):867–73. doi: 10.1067/mjd.2002.120470.
  52. Singh S, Kalb RE, de Jong EMGJ, Shear NH, Lebwohl M, Langholff W, Hopkins L, Srivastava B, Armstrong AW. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol. 2018;19(6):879–86. doi: 10.1007/s40257-018-0388-z.
  53. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005;211(2): 103–6. doi: 10.1159/000086437.
  54. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, Cuscito R. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology. 2008;217(4):365–73. doi: 10.1159/000156599.
  55. Ogdie A, Gelfand JM. Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence. Curr Rheumatol Rep. 2015;17(10):64. doi: 10.1007/s11926-015-0540-1.
  56. Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, Gladman DD. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol. 2016;68(4):915–23. doi: 10.1002/art.39494.
  57. Yan D, Ahn R, Leslie S, Liao W. Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis. Dermatol Ther (Heidelb). 2018;8(4):593–604. doi: 10.1007/s13555-018-0266-x.
  58. Коротаева ТВ, Корсакова ЮЛ, Логинова ЕЮ, Губарь ЕЕ, Чамурлиева МН. Псориатический артрит. Клинические рекомендации по диагностике и лечению. Современная ревматология. 2018;12(2):22–35. doi: 10.14412/1996-7012-2018-2-22-35.
  59. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewé RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–12. doi: 10.1136/annrheumdis-2020-217159.
  60. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180.
  61. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–106. doi: 10.1136/gutjnl-2019-318484.
  62. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1): 3–25. doi: 10.1093/ecco-jcc/jjw168.
  63. Reinisch W, Reinink AR, Higgins PD. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(4):635–42. doi: 10.1016/j.cgh.2014.03.037.
  64. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–61. doi: 10.1053/j.gastro.2020.01.006.
  65. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9(2):156–63. doi: 10.1093/ecco-jcc/jju016.
  66. Ивашкин ВТ, Шелыгин ЮА, Белоусова ЕА, Абдулганиева ДИ, Алексеева ОА, Ачкасов СИ, Валуйских ЕЮ, Варданян АВ, Веселов АВ, Веселов ВВ, Головенко ОВ, Губонина ИВ, Жигалова ТН, Кашников ВН, Князев ОВ, Макарчук ПА, Москалев АИ, Нанаева БА, Низов АА, Никитина НВ, Николаева НН, Павленко ВВ, Полуэктова ЕА, Светлова ИО, Тарасова ЛВ, Ткачев АВ, Фролов СА, Хлынова ОВ, Чашкова ЕЮ, Шапина МВ, Шептулин АА, Шифрин ОС, Щукина ОБ. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7–36. doi: 10.33878/2073-7556-2019-18-4-7-36.
  67. Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN, Burden AD, Smith CH; BADBIR study group and the PSORT consortium. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158–66. doi: 10.1111/bjd.18333.
  68. Gulliver W, Lynde C, Dutz JP, Vender RB, Yeung J, Bourcier M, Dion PL, Hong CH, Searles G, Poulin Y. Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis. J Cutan Med Surg. 2015;19(1): 22–7. doi: 10.2310/7750.2014.13151.
  69. ООО «Российское общество дерматовенерологов и косметологов». Псориаз: клинические рекомендации [Интернет]. Доступно на: http://cr.rosminzdrav.ru/schema.html?id=866#/text.
  70. Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vilarrasa E, Del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral F, Armesto S, Eiris N, Mitxelena J, Vilar-Alejo J, A Martin M, Soria C; from the Spanish Group of Psoriasis. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018;29(4):334–46. doi: 10.1080/09546634.2017.1395794.
  71. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J; Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210–9. doi: 10.2310/7750.2011.10066.
  72. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi: 10.1007/s00403-010-1080-1.
  73. Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S, Soyer HP, Wu J, Chan J, Nash P, Rawlin M, Radulski B, Foley P. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54(2):148–54. doi: 10.1111/ajd.12014.
  74. Puig L, Carrascosa JM, Carretero G, de la Cueva P, Lafuente-Urrez RF, Belinchón I, Sánchez-Regaña M, García-Bustínduy M, Ribera M, Alsina M, Ferrándiz C, Fonseca E, García-Patos V, Herrera E, López-Estebaranz JL, Marrón SE, Moreno JC, Notario J, Rivera R, Rodriguez-Cerdeira C, Romero A, Ruiz-Villaverde R, Taberner R, Vidal D; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(8): 694–709. doi: 10.1016/j.adengl.2013.04.013.
  75. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning VA, Warren RB, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–36. doi: 10.1111/bjd.15665.
  76. Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–83. doi: 10.1111/jdv.15340.
  77. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3–17. doi: 10.1136/annrheumdis-2017-211734.
  78. Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2016;68(2):267–74. doi: 10.1002/acr.22576.
  79. Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open. 2017;3(1):e000415. doi: 10.1136/rmdopen-2016-000415.
  80. Gossec L, McGonagle D, Korotaeva T, Lubrano E, de Miguel E, Østergaard M, Behrens F. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018;45(1):6–13. doi: 10.3899/jrheum.170449.
  81. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110(9):1324–38. doi: 10.1038/ajg.2015.233.
  82. Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017;45(8):1058–72. doi: 10.1111/apt.13995.
  83. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. doi: 10.14309/ajg.0000000000000152.
  84. Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Dig Dis. 2019;37(4):266–83. doi: 10.1159/000496739.
  85. Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114(6):874–83. doi: 10.14309/ajg.0000000000000183.
  86. Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS. What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis? J Rheumatol. 2019;46(1): 38–42. doi: 10.3899/jrheum.180267.
  87. Takeshita J. Taking aim at identifying treatment targets for psoriasis. Br J Dermatol. 2020;182(5):1075–6. doi: 10.1111/bjd.18635.
  88. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, Grier A, Molloy M, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):R94. doi: 10.1186/ar3021.
  89. Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study. Arthritis Care Res (Hoboken). 2018;70(10): 1529–35. doi: 10.1002/acr.23537.
  90. van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019;78(5):610–6. doi: 10.1136/annrheumdis-2018-214746.
  91. Коротаева ТВ, Логинова ЕЮ, Гетия ТС, Насонов ЕЛ. Результаты применения стратегии «Лечение до достижения цели» у больных ранним псориатическим артритом через 1 год после начала терапии: данные исследования РЕМАРКА. Терапевтический архив. 2018;90(5):22–9. doi: 10.26442/terarkh201890522-29
  92. Schoels MM, Landesmann U, Alasti F, Baker D, Smolen JS, Aletaha D. Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. Rheumatology (Oxford). 2018;57(6):969–76. doi: 10.1093/rheumatology/key004.
  93. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386(10006):1825–34. doi: 10.1016/S0140-6736(15)00068-9.
  94. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060–71. doi: 10.1002/art.39573.
  95. Thompson W, Argáez C. Early Biologic Treatment versus Conventional Treatment for the Management of Crohn’s Disease: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
  96. Ивашкин ВТ, Шелыгин ЮА, Абдулганиева ДИ, Абдулхаков РА, Алексеева ОП, Алексеенко СА, Ачкасов СИ, Багненко СФ, Бакулин ИГ, Барановский АЮ, Барышева ОЮ, Белоусова ЕА, Болихов КВ, Валуйских ЕЮ, Варданян АВ, Веселов АВ, Веселов ВВ, Головенко ОВ, Губонина ИВ, Жигалова ТН, Карпухин ОЮ, Кашников ВН, Кизова ЕА, Князев ОВ, Костенко НВ, Куловская ДП, Куляпин АВ, Лахин АВ, Макарчук ПА, Москалев АИ, Нанаева БА, Низов АА, Никитина НВ, Николаева НН, Никулина ИВ, Одинцова АХ, Осипенко МФ, Павленко ВВ, Парфенов АИ, Полуэктова ЕА, Румянцев ВГ, Светлова ИО, Ситкин СИ, Тарасова ЛВ, Ткачев АВ, Успенская ЮБ, Фролов СА, Хлынова ОВ, Чашкова ЕЮ, Шапина МВ, Шифрин ОС, Шкурко ТВ, Щукина ОБ. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8–38. doi: 10.33878/2073-7556-2020-19-2-8-38.
  97. Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2019;156(3): 748–64. doi: 10.1053/j.gastro.2018.12.009.
  98. Коротаева ТВ, Логинова ЕЮ, Каратеев ДЕ, Глазков АА, Насонов ЕЛ. Стратегия «Лечение до достижения цели» при раннем псориатическом артрите (предварительные результаты исследования РЕМАРКА). Научно-практическая ревматология. 2014;52(4): 376–80. doi: 10.14412/1995-4484-2014-376-380.
  99. Loginova EY, Korotaeva TV, Koltakova A, Gubar E. SAT0384. Comparative analysis of frequency and timing of minimal disease activity (MDA) attainment in early and long-term psoriatic arthritis (PSA) patients (PTS) after biological (B) dmards treatment initiation in clinical practice: Russian PSA. Ann Rheum Dis. 2019;78(Suppl 2):1276.
  100. Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol. 2008;14(17):2670–7. doi: 10.3748/wjg.14.2670.
  101. Pappu R, Ramirez-Carrozzi V, Ota N, Ouyang W, Hu Y. The IL-17 family cytokines in immunity and disease. J Clin Immunol. 2010;30(2):185– 95. doi: 10.1007/s10875-010-9369-6.
  102. Круглова ЛС, Львов АН, Каграманова АВ, Князев ОВ. Псориаз и воспалительные заболевания кишечника: пути патогенеза и вопросы выбора генно-инженерных препаратов (обзор литературы). Альманах клинической медицины. 2019;47(6):568–78. doi: 10.18786/2072-0505-2019-47-062.
  103. Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S. Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. Clin Pharmacol Ther. 2017;102(4): 633–41. doi: 10.1002/cpt.791.
  104. Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf. 2016;15(4):493– 501. doi: 10.1517/14740338.2016.1145653.
  105. Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep. 2019;21(2):1. doi: 10.1007/s11894-019-0669-6.
  106. Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Menter A; PSOLAR Steering Committee. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171(1):137–47. doi: 10.1111/bjd.13013.
  107. Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–14.
  108. Vilarrasa E, Notario J, Bordas X, López-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74(6):1066–72. doi: 10.1016/j.jaad.2016.01.037.
  109. Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, McElhone K, Lunt M, Barker JN, Burden AD, Ormerod AD, Reynolds NJ, Smith CH, Griffiths CE. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015;173(2):510–8. doi: 10.1111/bjd.13908.
  110. van den Reek JM, Zweegers J, Kievit W, Otero ME, van Lümig PP, Driessen RJ, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, van de Kerkhof PC, Seyger MM, de Jong EM. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014;171(5): 1189–96. doi: 10.1111/bjd.13087.
  111. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091– 6. doi: 10.1111/j.1365-2133.2011.10213.x.
  112. Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, Rasmussen MK, Skov L. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2): 509–19. doi: 10.1111/bjd.16102.
  113. Lunder T, Zorko MS, Kolar NK, Suhodolcan AB, Marovt M, Leskovec NK, Marko PB. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019;58(6): 631–41. doi: 10.1111/ijd.14429.
  114. Ko Y, Paramsothy S, Leong RW. P361 The effect of immunomodulators and other factors on the persistence of biological agents for Crohn's disease and ulcerative colitis: data from the Australian population-based registry. J Crohns Colitis. 2020;14(S1):S342–3. doi: 10.1093/ecco-jcc/jjz203.490.
  115. Savage L, Goodfield M, Horton L, Watad A, Hensor E, Emery P, Wakefield R, Wittmann M, McGonagle D. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. Arthritis Rheumatol. 2019;71(4):626–31. doi: 10.1002/art.40778.
  116. Kampylafka E, Simon D, d'Oliveira I, Linz C, Lerchen V, Englbrecht M, Rech J, Kleyer A, Sticherling M, Schett G, Hueber AJ. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1): 178. doi: 10.1186/s13075-019-1957-0.
  117. Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018;19(1): 1–13. doi: 10.1007/s40257-017-0328-3.
  118. Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2): 383–94. doi: 10.1016/j.jaad.2017.06.043.
  119. Varu A, Wilson FR, Dyrda P, Hazel M, Hutton B, Cameron C. Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. Curr Med Res Opin. 2019;35(5): 733–56. doi: 10.1080/03007995.2019.1580094.
  120. Инструкция по медицинскому применению лекарственного препарата Стелара [Интернет]. Доступно на: https://grls.rosminzdrav.ru.
  121. Dures E, Taylor J, Shepperd S, Mukherjee S, Robson J, Vlaev I, Walsh N, Coates LC. Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis. Ann Rheum Dis. 2020;79(8):1031–6. doi: 10.1136/annrheumdis-2020-217301.

Supplementary files

There are no supplementary files to display.

Copyright (c) 2020 Abdulganieva D.I., Bakulev A.L., Belousova E.A., Veselov A.V., Korotaeva T.V., Lila A.M., Loginova E.Y., Sokolovskiy E.V., Khobeysh M.M., Shapina M.V., Shchukina O.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies